You are here

FDA Rejects Neulasta Biosimilar Application

Agency requests reanalysis of subject samples

The FDA has issued a complete response letter (CRL) with regard to a biologics license application for CHS-1701, a biosimilar candidate for pegfilgrastim (Neulasta, Amgen) developed by Coherus BioSciences. The CRL primarily focused on the agency’s request for a reanalysis of a subset of subject samples with a revised immunogenicity assay, and on requests for additional manufacturing-related process information.

The FDA did not request a clinical study to be performed in oncology patients. In addition, the CRL did not indicate that additional process-qualification lots would be required or raise concerns regarding the good manufacturing practice (GMP) status of CHS-1701 bulk manufacturing and fill-finish vendors.

Coherus Biosciences said it will work with the FDA to address the information requests.

Amgen’s pegfilgastrim injection for subcutaneous use is indicated: 1) to reduce the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia, and 2) to increase survival in patients acutely exposed to myelosuppressive doses of radiation (ematopoietic subsyndrome of cute radiation syndrome).

Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor (G-CSF, filgrastim) and monomethoxypolyethylene glycol. Filgrastim is obtained from the bacterial fermentation of a strain of Escherichia coli transformed with a genetically engineered plasmid containing the human G-CSF gene.

Sources: Coherus BioSciences; June 12, 2017; Neulasta Prescribing Information; December 2016.

Recent Headlines

U.S., Australia, and Canada Approve Endometrial Cancer Regimen
Single daily pill combines hypertension, cholesterol drugs
Drug With Androgen Deprivation Therapy Cut Risk of Death by 33% Compared With Placebo + ADT
A Diabetes Drug For People Without Diabetes
Roche Drug Outperformed Standard of Care in Phase 2 Study
Related Settlement Would End Many but Not All Lawsuits
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy